文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

单次MM120(麦角酸二乙酰胺)治疗广泛性焦虑障碍:一项随机临床试验

Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01

这项2b期多中心随机双盲安慰剂对照研究纳入198例中重度广泛性焦虑障碍成人,单次给予MM120 25、50、100、200 µg或安慰剂。第4周HAM-A评分变化呈显著剂量反应关系,100 µg和200 µg组较安慰剂显著降低,25 µg和50 µg组未达显著。常见不良事件为视知觉改变、恶心和头痛。

要点

  • 单次MM120在第4周HAM-A评分变化上呈显著剂量反应关系。
  • 100 µg和200 µg组较安慰剂显著降低HAM-A评分,25 µg和50 µg组未达显著。
  • 最常见不良事件为视知觉改变,发生率随剂量升高而增加。

核心结论

  • 在中重度广泛性焦虑障碍参与者中,单次MM120产生剂量依赖性焦虑减轻。
  • 这些结果支持MM120的剂量依赖性疗效,并为3期关键试验的剂量选择提供依据。

研究设计与样本

  • 这项2b期、多中心、随机、双盲、安慰剂对照研究纳入198例18至74岁、原发广泛性焦虑障碍诊断且HAM-A评分≥20的中重度症状成人。
  • 研究于2022年8月至2023年8月在美国22个门诊精神科研究站点开展,末次随访日期为2023年11月27日。
  • 参与者随机接受单次(游离碱等效)25 µg(n=39)、50 µg(n=40)、100 µg(n=40)、200 µg(n=40)MM120或安慰剂(n=39)。
  • 焦虑和抑郁终点评估由独立中心评定员进行,评定员对试验方案、治疗分配和研究访视日期设盲。

主要发现

  • 198例随机参与者中,194例纳入全分析集(平均年龄41.3岁[SD 13.6];56.7%为女性;3.6%为亚洲人、7.7%为黑人或非裔美国人、83.0%为白人)。
  • 第4周HAM-A评分变化采用MCP-Mod法评估的剂量反应关系在100 µg和200 µg剂量组较安慰剂达统计学显著:100 µg组最小二乘均值差为-5.0分(95%CI -9.6至-0.4分),200 µg组为-6.0分(95%CI -9.8至-2.0分)。
  • 25 µg和50 µg剂量组较安慰剂未达显著:25 µg组最小二乘均值差为-1.2分(95%CI -6.0至3.5分),50 µg组为-1.8分(95%CI -7.6至4.0分)。
  • 不良事件与MM120的预期效应一致;最常见不良事件为视知觉改变(错觉、假性幻觉和视幻觉),25 µg组发生率46.2%、50 µg组75.0%、100 µg组92.5%、200 µg组100%、安慰剂组10.3%。
  • 恶心发生率分别为25 µg组7.7%、50 µg组27.5%、100 µg组40.0%、200 µg组60.0%、安慰剂组7.7%;头痛发生率分别为12.8%、22.5%、35.0%、27.5%、23.1%。

关键数值与推荐

  • 主要结局为第4周HAM-A评分变化采用MCP-Mod法评估的剂量反应关系(评分范围0-56分,分数越高表示越严重;≤7分表示无或极轻焦虑,8-14分轻度,15-23分中度,≥24分重度)。
  • 最小临床重要差异为2.5分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Effective and well-tolerated pharmacotherapies for generalized anxiety disorder (GAD), which is one of the most common psychiatric disorders, are needed. OBJECTIVE: To determine the dose-response relationship of MM120 (lysergide D-tartrate) in adults with moderate to severe GAD. DESIGN, SETTINGS, AND PARTICIPANTS: This phase 2b, multicenter, randomized, double-blind, placebo-controlled study enrolled 198 adults aged 18 to 74 years with a primary GAD diagnosis who presented with moderate to severe symptoms (defined by a Hamilton Anxiety Rating Scale [HAM-A] score ≥20) and was conducted at 22 outpatient psychiatric research sites in the US from August 2022 to August 2023. The anxiety and depression end point assessments were conducted by independent central raters who were blinded to the trial protocol, treatment allocation, and study visit date. The last date of follow-up was November 27, 2023. INTERVENTIONS: Participants were randomized to receive a single (freebase equivalent) treatment dose with 25 µg (n = 39), 50 µg (n = 40), 100 µg (n = 40), or 200 µg (n = 40) of MM120 or placebo (n = 39). MAIN OUTCOME AND MEASURES: The primary outcome was a dose-response relationship assessed using the multiple comparison procedure modeling (MCP-Mod) method for change in HAM-A score at 4 weeks (score range, 0-56; higher scores indicate greater severity; ≤7 indicates no or minimal anxiety; 8-14, mild; 15-23, moderate; and ≥24, severe). The minimal clinically important difference was 2.5 points. RESULTS: Of the 198 participants randomized, 194 were included in the full analysis set (mean age, 41.3 [SD, 13.6] years; 56.7% were female; and 3.6% were Asian, 7.7% were Black or African American, and 83.0% were White). The dose-response relationship assessed using the MCP-Mod method for change in HAM-A score at week 4 was statistically significant for the 100-µg and the 200-µg dose groups vs placebo (least-squares mean difference, -5.0 points [95% CI, -9.6 to -0.4 points] with 100 µg of MM120 and -6.0 points [95% CI, -9.8 to -2.0 points] with 200 µg of MM120) but the 25-µg and 50-µg dose groups did not reach significance vs placebo (least-squares mean difference, -1.2 points [95% CI, -6.0 to 3.5 points] with 25 µg of MM120 and -1.8 points [95% CI, -7.6 to 4.0 points] with 50 µg of MM120). The adverse events were consistent with the expected effects of MM120. The most common adverse events were visual perceptual changes (illusion, pseudo-hallucination, and visual hallucination), which occurred in 46.2% of participants who received 25 µg of MM120, in 75.0% who received 50 µg, in 92.5% who received 100 µg, in 100% who received 200 µg, and in 10.3% who received placebo; nausea occurred in 7.7%, 27.5%, 40.0%, 60.0%, and 7.7%, respectively; and headache occurred in 12.8%, 22.5%, 35.0%, 27.5%, and 23.1%. CONCLUSIONS AND RELEVANCE: In participants with moderate to severe GAD, a single dose of MM120 produced a dose-dependent reduction in anxiety. These results support the dose-dependent efficacy of MM120 and inform the dose selection for phase 3 pivotal trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05407064.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Robison R, Barrow R, Conant C, et al. Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial. JAMA. 2025. PMID: 40906494. doi:10.1001/jama.2025.13481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。